The Impact of Colorectal Cancer Screening on Surgical Outcomes

This study aims to investigate the pathological characteristics and surgical outcomes of stage III CRC patients detected through screening.

Data extracted from the database included the following patient information: age at diagnosis, gender, tumor location, neoadjuvant therapy, surgical procedures, histologic type, differentiation, vascular invasion, perineural invasion, pathological T stage, pathological N stage, and survival outcomes.

Study Overview

• Status: Not yet recruiting
• Conditions: Colorectal Cancer; Prognosis; Screening
• Intervention / Treatment: Other: Mode of detection

• Study Type: Observational
• Enrollment (Estimated): 4000

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200032
      • Xinxiang Li

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

patients who underwent surgical intervention for CRC at Fudan University Shanghai Cancer Center.

Description

Inclusion Criteria:

• Patients who underwent radical surgery for CRC, had confirmed stage III CRC through postoperative pathology, had no prior history of cancer before surgery, and had clear cancer detection information.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
screening; Patients who were detected through any screening test were categorized into the screening group	Other: Mode of detection; Mode of detection
nonscreening; Patients who were detected based on symptoms formed the non-screening group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
overall survival	The duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first. Assessed up to 100 months.	the duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first. Assessed up to 100 months.

Collaborators and Investigators

• Sponsor: Fudan University

Study record dates

Study Major Dates

• Study Start (Estimated): May 11, 2024
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): June 15, 2024

Study Registration Dates

• First Submitted: May 9, 2024
• First Submitted That Met QC Criteria: May 15, 2024
• First Posted (Actual): May 16, 2024

Study Record Updates

• Last Update Posted (Actual): May 16, 2024
• Last Update Submitted That Met QC Criteria: May 15, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: FudanUcf

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No